menu
    • menu
    [{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Atlant Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Atlant Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Atlant Clinical"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Atlant Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valenta Pharm JSC \/ Atlant Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Atlant Clinical"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Ingavirin

    Menu

    Ingavirin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules...

                            Details : Imidazolyl Ethanamide Pentandioic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory ...

                            Details : Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Influenza, Human.

                            Product Name : Ingavirin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respirator...

                            Details : Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.

                            Product Name : Ingavirin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2022

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

                            Details : Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Ingavirin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2022

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patien...

                            Details : Ingavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2017

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Atlant Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Childr...

                            Details : Ingavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2017

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Atlant Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

                            Details : Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.

                            Product Name : Ingavirin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2017

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infection...

                            Details : Ingavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Common Cold.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 16, 2017

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valenta Pharm JSC

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Atlant Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in ...

                            Details : Imidazolyl Ethanamide Pentandioic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Common Cold.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 31, 2015

                            Lead Product(s) : Ingavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Atlant Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth